Stereotaxis to Report Second Quarter Financial Results on August 9, 2022
ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. ET that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis second quarter 2022 financial results conference call |
| When: | Tuesday, August 9, 2022 at 10:00 a.m. ET (7:00 a.m. PT) |
| Dial In Number: | To access the live call, dial 888-394-8218 (US and Canada) or 1-856-344-9221 (International) and give the participant pass code 9211068. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately two hours following the end of the call. To request access for a replay of the conference call, please . |
About Stereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit
| Investor Contacts: David L. Fischel Chairman and Chief Executive Officer | Media Contact: Bethanne Schluter Director, Marketing & Communications |
| Kimberly Peery Chief Financial Officer | |
| 314-678-6100 | |
